<DOC>
	<DOCNO>NCT02004678</DOCNO>
	<brief_summary>DS-1150b develop Daiichi Sankyo treatment Type 2 Diabetes Mellitus . This Phase I , single-blind ( subject principal investigator blind , Sponsor unblinded ) , placebo‑controlled , randomize , 2‑part , sequential , single ascend dose , single center study assess safety , tolerability , pharmacokinetics , pharmacodynamics single oral dose DS‑1150b healthy subject subject Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Study Assess Safety , Pharmacokinetics Pharmacodynamics DS-1150b Healthy Subjects Subjects With Type-2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>All Subjects : All woman must negative serum pregnancy test screen negative urine pregnancy test Day 1 . Women must nonchildbearing potential , either : Surgically sterile ( ie , bilateral tubal ligation removal ovary and/or uterus least 6 month prior dose administration ) . &lt; 60 year age naturally postmenopausal ( spontaneous cessation menses ) least 24 consecutive month prior dose administration , follicle stimulate hormone ( FSH ) level screen ≥40 mIU/mL . &gt; 60 year age naturally postmenopausal ( spontaneous cessation menses ) least 24 consecutive month prior dose administration . Male subject agree contraception ( condom spermicide ) addition female partner ( childbearing potential ) use another form contraception ( eg , intrauterine device , diaphragm spermicide , oral 12 week follow last dose administration . In addition , male subject must donate sperm study period 12 week . Subjects must give write informed consent participate study prior screen . Subjects must good health determine screen medical history , physical examination finding , vital sign measurement , ECGs , serum chemistry , hematology , virology ( ie , HIV , HBV , HCV screen ) , urinalysis perform screening Day 1 . Subjects must agree abstain grapefruit/grapefruit juice Seville oranges 10 day first dose throughout study . All subject must negative fecal occult blood test . Part B ( Type 2 Diabetes Mellitus ) : Men woman childbearing potential , 18 year 60 year age , inclusive . A BMI 25 kg/m2 38 kg/m2 , inclusive . Diagnosis Type 2 DM minimum 3 month prior first dose . Subjects either : On metformin alone hemoglobin A1c ( HBA1c ) value 7 % 9.5 % , inclusive . Treatment naïve treatment free antidiabetic treatment least 3 month prior screen HBA1c value 7 % 10 % , inclusive . Subjects fast plasma glucose ≥100 mg/dL ≤250 mg/dL , screen Day 1 . All Subjects : History gastrointestinal ulcer erosion , rhabdomyolysis within 6 month dose administration . Subjects laboratory result outside normal range , consider clinically significant Investigator . Subjects serum K ULN clinical laboratory 's reference range screen Day 1 . Subjects CPK ULN screen Day 1 . Subjects lactate ULN screen Day 1 . Subjects QTcF interval duration &gt; 450 msec , obtain average 3 ECG recorder 's measurement triplicate screen ECGs ( 3 ECGs close succession least 1 min apart ) take least 10 minute quiet rest supine position . Subjects abnormal waveform morphology ECGs screen Day 1 would preclude accurate measurement QT interval duration . History serious disorder , include cardiovascular , hematologic , pulmonary , hepatic , renal , gastrointestinal , skeletal , connective tissue disease , uncontrolled endocrine/metabolic subject Type 2 DM Part B , oncologic ( within last 5 year ) , neurologic , psychiatric disease , disorder may prevent successful completion study . Subjects physical trauma , surgery significant illness within 4 week prior first dose . Donated lose &gt; 500 mL blood plasma within 3 month prior first dose Day 1 . Participated clinical study involve administration investigational drug ( new chemical entity ) , mark drug within 30 day prior administration first dose . Part B ( Type 2 Diabetes Mellitus ) History Type 1 diabetes and/or history acute chronic metabolic acidosis , include diabetic ketoacidosis . History severe microvascular macrovascular complication Type 2 DM , include proliferative retinopathy , macroalbuminuria , peripheral neuropathy , ischemic heart disease , stroke , peripheral vascular disease . History diabetic neuropathy . Need concomitant medication moderate strong CYP inhibitor include CYP3A4 , CYP2D6 , CYP2C9 , CYP2C19 , Pgp inhibitor . Need antidiabetic drug except metformin . Other common concomitant medication diabetic patient may allow ( eg , aspirin thyroid hormone ) upon agreement Sponsor PI . Subjects liver function ALT AST 1.25 × ULN , total bilirubin ULN screen Day 1 . Moderate severe renal dysfunction , define eGFR ( use MDRD equation ) &lt; 60 mL/min .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>